SCHEMBL6153064

SCHEMBL6153064

CCN(CC)CCOCc1ccccc1C=CC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HPGD P15428 1/20 0.49
PTGER3 P43115 10/20 0.46
PTGER2 P43116 9/20 0.46
PTGER4 P35408 8/20 0.46
PTGDR Q13258 4/20 0.44
TBXA2R P21731 3/20 0.44
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
PTGER1 P34995 3/20 0.43
SCN1A P35498 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
TBXAS1 P24557 1/20 0.43
PTGFR P43088 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153061 1.00 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2HPGDPTGER3
SCHEMBL8573281 0.76 PTGER3 (0.57) KDM4EPTGER3PTGER2PTGER4PTGDR
SCHEMBL1150939 0.75 PTGER3 (0.63) SMN1; SMN2PTGER3PTGER2PTGER4PTGDR
SCHEMBL3214322 0.75 PTGER3 (0.63) SMN1; SMN2PTGER3PTGER2PTGER4PTGDR
SCHEMBL309761 0.75 PTGER3 (0.63) SMN1; SMN2PTGER3PTGER2PTGER4PTGDR
SCHEMBL6152820 0.75 KDM4E (0.50) KDM4EALDH1A1SMN1; SMN2LMNACYP1A2
SCHEMBL6154507 0.73 HRH1 (0.50) KDM4EALDH1A1SMN1; SMN2PTGER3PTGER2
SCHEMBL6154514 0.73 HRH1 (0.50) KDM4EALDH1A1SMN1; SMN2PTGER3PTGER2
SCHEMBL3256824 0.71 PTGER3 (0.58) KDM4EALDH1A1PTGER3PTGER2PTGER4
SCHEMBL28893816 0.71 PTGER3 (0.58) KDM4EALDH1A1PTGER3PTGER2PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307449-B1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMA (JP) 2005-12-07 EP disclosed
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US disclosed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP disclosed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US disclosed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 KDM4E 1330/4885ALDH1A1 1798/4885SMN1; SMN2 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.